No. of donors assayed | Effector cells in upper chambers | Effector cells: Â % of CAp24+ cells 3Â days p.i. | Co-culture conditions | Target cells in lower chambers: % of CAp24+ cells after 2Â days of co-culture | ||
---|---|---|---|---|---|---|
Mock | ΔenvHIV-1 | ΔenvHIV-1 +AZT | ||||
5 | Ctrl | <0.1 | Complete medium | <0.1 | <0.1 | <0.1 |
5 | wtHIV-1 | 31.2 | Complete medium | <0.1 | 8.7 | <0.1 |
5 | wtHIV-1 | 32 | GW4869+ Spiroepoxide | <0.1 | 1.6 | 0.4 |
3 | wtHIV-1 | 30.9 | TAPI-2 | 0.2 | 1.8 | 0.3 |
2 | wtHIV-1 | 26.4 | IgGs | 0.2 | 6.9 | 0.3 |
2 | wtHIV-1 | 28.7 | Anti-TNFα Abs | 0.2 | 0.2 | <0.1 |
1 | ΔnefHIV-1 | 34.7 | Complete medium | 0.5 | 1.8 | 0.6 |
1 | ΔnefHIV-1 | 31.3 | GW4869+ Spiroepoxide | 0.3 | 0.9 | 0.3 |